You are here
Metastatic castration resistant prostate cancer (mCRPC)
Metabolic and Prostate-Specific Antigen Response After Abiraterone Acetate Withdrawal: A New Clinical Scenario for Castration-Resistant Prostate Cancer?
Orazio Caffo, Antonio Palermo, Antonello Veccia, Francesca Maines, Franca Chierichetti, Enzo Galligioni
Clinical Genitourinary Cancer, 4, 11, pages e10 - e14
Although so far there is only case based evidence, this may be an interesting phenomenon....
Carmel J. Pezaro, Aurelius Omlin, David Lorente, Daniel Nava Rodrigues, Roberta Ferraldeschi, Diletta Bianchini, Deborah Mukherji, Ruth Riisnaes, Amelia Altavilla, Mateus Crespo, Nina Tunariu, Johann S. de Bono, Gerhardt Attard
European Urology, 2, 65, pages 270 - 273
Visceral metastases in CRPC have been underdiagnosed in the past. Routine imaging studies to detect liver and lung...
Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer
R.J. van Soest, M.E. van Royen, E.S. de Morrée, J.M. Moll, W. Teubel, E.A.C. Wiemer, R.H.J. Mathijssen, R. de Wit, W.M. van Weerden
European Journal of Cancer, 18, 49, pages 3821 - 3830
This article gives some experimental backround to the clinical observation (albeit in only small series so far) of...
Biochemical and objective response to abiraterone acetate withdrawal: Incidence and clinical relevance of a new scenario for castration-resistant prostate cancer
O. Caffo, A. Palermo, A. Veccia, F. Maines, F. Chierichetti, A. Berruti, E. Galligioni.Urology, Volume 82, Issue 5, November 2013, Pages 1090-1093.
This, to the best of my knowledge , is the first report demonstrating an...
Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial
J.C. Araujo, G.C. Trudel, F. Saad, A.J. Armstrong, E.Y. Yu, J. Bellmunt, G. Wilding, J. McCaffrey, S.V. Serrano, V.B. Matveev, E. Efstathiou, S. Oudard, M.J. Morris, B. Sizer, P.J. Goebell, A. Heidenreich, J.S. de Bono, S. Begbie, J.H. Hong, E. Richardet,The Lancet Oncology, Volume 14, Issue 13, December 2013, Pages 1307-1316.
This study adds to the long list of failures when compounds were combined with Docetaxel in mCRPC patients....
D.A. Loblaw, C. Walker-Dilks, E. Winquist, S.J. Hotte.Clinical Oncology, Volume 25, Issue 7, Pages 406-430. July 2013.
This review give a timely overview over the rapidly changing landscape in mCRPC treatment. However, due to the...
C. Parker, S. Nilsson, D. Heinrich, S.I. Helle, J.M. O’Sullivan, S.D. Fosså, A. Chodacki, P. Wiechno, J. Logue, M. Seke, A. Widmark, D.C. Johannessen, P. Hoskin, D. Bottomley, N.D. James, A. Solberg, I. Syndikus, J. Kliment, S. Wedel, S. Boehmer, M. DaNew England Journal of Medicine, Volume 369, Issue 3, Pages 213-223. 18 July 2013.
Rad 223 is a new alpha-emitter. In the reported phase-III study overall survival in mCRPC patients was significantly...
Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial
E. Basch, K. Autio, C.J.Ryan, P. Mulders, N. Shore, T. Kheoh, K. Fizazi, C.J. Logothetis, D. Rathkopf, M.R. Smith, P.N. Mainwaring, Y. Hao, T. Griffin, S. Li, M.L. Meyers, A. Molina, C. Cleeland.The Lancet Oncology, Volume 14, Issue 12, November 2013, Pages 1193-1199
In this preplanned analysis of the Cou-302 trial, results of patient reported outcomes are described. Abiraterone plus prednisone...
Estimating scenarios for survival time in men starting systemic therapies for castration-resistant prostate cancer: A systematic review of randomised trials
T.A. West, B.E. Kiely, M.R. Stockler
European Journal of Cancer, 11, 50, pages 1916 - 1924
Editorial comment Prof A Merseburger
This systematic review of most available published trials on mCRPC underlines the palliative...
Biochemical and objective response to abiraterone acetate withdrawal: Incidence and clinical relevance of a new scenario for castration-resistant prostate cancerBy O. Caffo, A. Palermo, A. Veccia, F. Maines, F. Chierichetti, A. Berruti and E. Galligioni.Urology, Volume 82, Issue 5,...
This, to the best of my knowledge , is the first report demonstrating an abiraterone withdrawal effect (similar...